메뉴 건너뛰기




Volumn 34, Issue 1, 2014, Pages 181-196

Mastocytosis

Author keywords

Bone marrow; KIT; Mast cell; Mastocytosis; Skin; Urticaria

Indexed keywords

ADRENALIN; ALPHA2B INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CETIRIZINE; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ESTROGEN; FAMOTIDINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; IMATINIB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MASITINIB; MIDOSTAURIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; PSORALEN; RANITIDINE;

EID: 84888005221     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.09.001     Document Type: Review
Times cited : (84)

References (77)
  • 2
    • 0026073372 scopus 로고
    • Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells
    • Kirshenbaum A.S., Kessler S.W., Goff J.P., et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. JImmunol 1991, 146(5):1410-1415.
    • (1991) JImmunol , vol.146 , Issue.5 , pp. 1410-1415
    • Kirshenbaum, A.S.1    Kessler, S.W.2    Goff, J.P.3
  • 3
    • 0033215406 scopus 로고    scopus 로고
    • Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)
    • Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94(7):2333-2342.
    • (1999) Blood , vol.94 , Issue.7 , pp. 2333-2342
    • Kirshenbaum, A.S.1    Goff, J.P.2    Semere, T.3
  • 5
    • 0028152595 scopus 로고
    • Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population
    • Rottem M., Okada T., Goff J.P., et al. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. Blood 1994, 84(8):2489-2496.
    • (1994) Blood , vol.84 , Issue.8 , pp. 2489-2496
    • Rottem, M.1    Okada, T.2    Goff, J.P.3
  • 6
    • 0029082273 scopus 로고
    • Mast cell ontogeny and apoptosis
    • Metcalfe D.D., Mekori J.A., Rottem M. Mast cell ontogeny and apoptosis. Exp Dermatol 1995, 4(4 Pt 2):227-230.
    • (1995) Exp Dermatol , vol.4 , Issue.4 PART 2 , pp. 227-230
    • Metcalfe, D.D.1    Mekori, J.A.2    Rottem, M.3
  • 7
    • 13044305857 scopus 로고    scopus 로고
    • Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
    • Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96(4):1609-1614.
    • (1999) Proc Natl Acad Sci USA , vol.96 , Issue.4 , pp. 1609-1614
    • Longley, B.J.1    Metcalfe, D.D.2    Tharp, M.3
  • 8
    • 34250796815 scopus 로고    scopus 로고
    • Mastocytosis: state of the art
    • Horny H.P., Sotlar K., Valent P. Mastocytosis: state of the art. Pathobiology 2007, 74(2):121-132.
    • (2007) Pathobiology , vol.74 , Issue.2 , pp. 121-132
    • Horny, H.P.1    Sotlar, K.2    Valent, P.3
  • 9
    • 79952336888 scopus 로고    scopus 로고
    • Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    • Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96(3):459-463.
    • (2011) Haematologica , vol.96 , Issue.3 , pp. 459-463
    • Wilson, T.M.1    Maric, I.2    Simakova, O.3
  • 10
    • 0037238684 scopus 로고    scopus 로고
    • Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene
    • Sundstrom M., Vliagoftis H., Karlberg P., et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003, 108(1):89-97.
    • (2003) Immunology , vol.108 , Issue.1 , pp. 89-97
    • Sundstrom, M.1    Vliagoftis, H.2    Karlberg, P.3
  • 11
    • 33747343192 scopus 로고    scopus 로고
    • Diagnostic evaluation and classification of mastocytosis
    • Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):515-534.
    • (2006) Immunol Allergy Clin North Am , vol.26 , Issue.3 , pp. 515-534
    • Valent, P.1
  • 12
    • 34548272148 scopus 로고    scopus 로고
    • KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    • Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. JAllergy Clin Immunol 2007, 120(3):680-687.
    • (2007) JAllergy Clin Immunol , vol.120 , Issue.3 , pp. 680-687
    • Maric, I.1    Robyn, J.2    Metcalfe, D.D.3
  • 13
    • 52249118345 scopus 로고    scopus 로고
    • Regulatory effects of histamine and histamine receptor expression in human allergic immune responses
    • Akdis C.A., Jutel M., Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008, 94:67-82.
    • (2008) Chem Immunol Allergy , vol.94 , pp. 67-82
    • Akdis, C.A.1    Jutel, M.2    Akdis, M.3
  • 14
    • 79958843169 scopus 로고    scopus 로고
    • Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations
    • Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12(4):259-270.
    • (2011) Am J Clin Dermatol , vol.12 , Issue.4 , pp. 259-270
    • Castells, M.1    Metcalfe, D.D.2    Escribano, L.3
  • 15
    • 4544357034 scopus 로고    scopus 로고
    • Systemic mastocytosis: current concepts and treatment advances
    • Tefferi A., Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep 2004, 3(3):197-202.
    • (2004) Curr Hematol Rep , vol.3 , Issue.3 , pp. 197-202
    • Tefferi, A.1    Pardanani, A.2
  • 16
    • 33646051264 scopus 로고    scopus 로고
    • Current options in the treatment of mast cell mediator-related symptoms in mastocytosis
    • Escribano L., Akin C., Castells M., et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006, 5(1):61-77.
    • (2006) Inflamm Allergy Drug Targets , vol.5 , Issue.1 , pp. 61-77
    • Escribano, L.1    Akin, C.2    Castells, M.3
  • 17
    • 0000124580 scopus 로고
    • The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases
    • Caplan R.M. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963, 87:146-157.
    • (1963) Arch Dermatol , vol.87 , pp. 146-157
    • Caplan, R.M.1
  • 18
    • 34249333084 scopus 로고    scopus 로고
    • Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria
    • Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
    • (2007) Eur J Clin Invest , vol.37 , Issue.6 , pp. 435-453
    • Valent, P.1    Akin, C.2    Escribano, L.3
  • 19
    • 0037380382 scopus 로고    scopus 로고
    • Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology
    • Brockow K., Akin C., Huber M., et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. JAm Acad Dermatol 2003, 48(4):508-516.
    • (2003) JAm Acad Dermatol , vol.48 , Issue.4 , pp. 508-516
    • Brockow, K.1    Akin, C.2    Huber, M.3
  • 20
    • 0036280010 scopus 로고    scopus 로고
    • Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease
    • Brockow K., Scott L.M., Worobec A.S., et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002, 138(6):785-790.
    • (2002) Arch Dermatol , vol.138 , Issue.6 , pp. 785-790
    • Brockow, K.1    Scott, L.M.2    Worobec, A.S.3
  • 21
    • 0034994550 scopus 로고    scopus 로고
    • Clinical and histopathological aspects of cutaneous mastocytosis
    • Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25(7):519-528.
    • (2001) Leuk Res , vol.25 , Issue.7 , pp. 519-528
    • Wolff, K.1    Komar, M.2    Petzelbauer, P.3
  • 22
    • 0023764931 scopus 로고
    • Gastrointestinal dysfunction in systemic mastocytosis. A prospective study
    • Cherner J.A., Jensen R.T., Dubois A., et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988, 95(3):657-667.
    • (1988) Gastroenterology , vol.95 , Issue.3 , pp. 657-667
    • Cherner, J.A.1    Jensen, R.T.2    Dubois, A.3
  • 23
    • 84884904326 scopus 로고    scopus 로고
    • Gastrointestinal manifestations inmastocytosis: a study of 83 patients
    • 866-873.e3
    • Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations inmastocytosis: a study of 83 patients. JAllergy Clin Immunol 2013, 132(4). 866-873.e3.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.4
    • Sokol, H.1    Georgin-Lavialle, S.2    Canioni, D.3
  • 24
    • 0025921179 scopus 로고
    • Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital
    • [discussion: 13S-4S]
    • Horan R.F., Austen K.F. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. JInvest Dermatol 1991, 96(3):5S-13S. [discussion: 13S-4S].
    • (1991) JInvest Dermatol , vol.96 , Issue.3
    • Horan, R.F.1    Austen, K.F.2
  • 25
    • 0033946286 scopus 로고    scopus 로고
    • Gastrointestinal abnormalities and involvement in systemic mastocytosis
    • Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14(3):579-623.
    • (2000) Hematol Oncol Clin North Am , vol.14 , Issue.3 , pp. 579-623
    • Jensen, R.T.1
  • 26
    • 0036204668 scopus 로고    scopus 로고
    • Cytogenetic and molecular genetic abnormalities in systemic mastocytosis
    • Gupta R., Bain B.J., Knight C.L. Cytogenetic and molecular genetic abnormalities in systemic mastocytosis. Acta Haematol 2002, 107(2):123-128.
    • (2002) Acta Haematol , vol.107 , Issue.2 , pp. 123-128
    • Gupta, R.1    Bain, B.J.2    Knight, C.L.3
  • 27
    • 0017293388 scopus 로고
    • Gastrointestinal involvement in systemic mastocytosis
    • Ammann R.W., Vetter D., Deyhle P., et al. Gastrointestinal involvement in systemic mastocytosis. Gut 1976, 17(2):107-112.
    • (1976) Gut , vol.17 , Issue.2 , pp. 107-112
    • Ammann, R.W.1    Vetter, D.2    Deyhle, P.3
  • 29
    • 0020052921 scopus 로고
    • Anew syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide
    • Wesley J.R., Vinik A.I., O'Dorisio T.M., et al. Anew syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide. Gastroenterology 1982, 82(5 Pt 1):963-967.
    • (1982) Gastroenterology , vol.82 , Issue.5 PART 1 , pp. 963-967
    • Wesley, J.R.1    Vinik, A.I.2    O'Dorisio, T.M.3
  • 30
  • 31
    • 48349113831 scopus 로고    scopus 로고
    • Case-control cohort study of patients' perceptions of disability in mastocytosis
    • Hermine O., Lortholary O., Leventhal P.S., et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 2008, 3(5):e2266.
    • (2008) PLoS One , vol.3 , Issue.5
    • Hermine, O.1    Lortholary, O.2    Leventhal, P.S.3
  • 32
    • 61549092158 scopus 로고    scopus 로고
    • Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels
    • Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123(3):680-686.
    • (2009) JAllergy Clin Immunol , vol.123 , Issue.3 , pp. 680-686
    • Bonadonna, P.1    Perbellini, O.2    Passalacqua, G.3
  • 33
    • 0025953101 scopus 로고
    • Effect of major axial skeleton trauma on preexisting lumbosacral spondylolisthesis
    • Floman Y., Margulies J.Y., Nyska M., et al. Effect of major axial skeleton trauma on preexisting lumbosacral spondylolisthesis. JSpinal Disord 1991, 4(3):353-358.
    • (1991) JSpinal Disord , vol.4 , Issue.3 , pp. 353-358
    • Floman, Y.1    Margulies, J.Y.2    Nyska, M.3
  • 34
    • 0024988912 scopus 로고
    • Osteoporosis as the sole presentation of bone marrow mastocytosis
    • Lidor C., Frisch B., Gazit D., et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. JBone Miner Res 1990, 5(8):871-876.
    • (1990) JBone Miner Res , vol.5 , Issue.8 , pp. 871-876
    • Lidor, C.1    Frisch, B.2    Gazit, D.3
  • 35
    • 71949131585 scopus 로고    scopus 로고
    • Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
    • Rueff F., Przybilla B., Bilo M.B., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. JAllergy Clin Immunol 2009, 124(5):1047-1054.
    • (2009) JAllergy Clin Immunol , vol.124 , Issue.5 , pp. 1047-1054
    • Rueff, F.1    Przybilla, B.2    Bilo, M.B.3
  • 36
    • 0023859217 scopus 로고
    • Pathology of the lymph node and spleen in systemic mast cell disease
    • Travis W.D., Li C.Y. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol 1988, 1(1):4-14.
    • (1988) Mod Pathol , vol.1 , Issue.1 , pp. 4-14
    • Travis, W.D.1    Li, C.Y.2
  • 37
    • 0029143689 scopus 로고
    • Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases
    • Mican J.M., Di Bisceglie A.M., Fong T.L., et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995, 22(4 Pt 1):1163-1170.
    • (1995) Hepatology , vol.22 , Issue.4 PART 1 , pp. 1163-1170
    • Mican, J.M.1    Di Bisceglie, A.M.2    Fong, T.L.3
  • 38
    • 0023741248 scopus 로고
    • Asurvey of the number and distribution of mast cells in the skin of patients with mast cell disorders
    • Garriga M.M., Friedman M.M., Metcalfe D.D. Asurvey of the number and distribution of mast cells in the skin of patients with mast cell disorders. JAllergy Clin Immunol 1988, 82(3 Pt 1):425-432.
    • (1988) JAllergy Clin Immunol , vol.82 , Issue.3 PART 1 , pp. 425-432
    • Garriga, M.M.1    Friedman, M.M.2    Metcalfe, D.D.3
  • 39
    • 0023129616 scopus 로고
    • Mast cell numbers in diffuse scleroderma
    • Nishioka K., Kobayashi Y., Katayama I., et al. Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987, 123(2):205-208.
    • (1987) Arch Dermatol , vol.123 , Issue.2 , pp. 205-208
    • Nishioka, K.1    Kobayashi, Y.2    Katayama, I.3
  • 40
    • 0023024216 scopus 로고
    • Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells
    • Elias J., Boss E., Kaplan A.P. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. JAllergy Clin Immunol 1986, 78(5 Pt 1):914-918.
    • (1986) JAllergy Clin Immunol , vol.78 , Issue.5 PART 1 , pp. 914-918
    • Elias, J.1    Boss, E.2    Kaplan, A.P.3
  • 41
    • 0022616445 scopus 로고
    • Increase in skin mast cells following chronic house dust mite exposure
    • Mitchell E.B., Crow J., Williams G., et al. Increase in skin mast cells following chronic house dust mite exposure. Br J Dermatol 1986, 114(1):65-73.
    • (1986) Br J Dermatol , vol.114 , Issue.1 , pp. 65-73
    • Mitchell, E.B.1    Crow, J.2    Williams, G.3
  • 42
    • 77956153867 scopus 로고    scopus 로고
    • Mastocytosis-an update
    • [quiz: 712]
    • Amon U., Hartmann K., Horny H.P., et al. Mastocytosis-an update. JDtsch Dermatol Ges 2010, 8(9):695-711. [quiz: 712].
    • (2010) JDtsch Dermatol Ges , vol.8 , Issue.9 , pp. 695-711
    • Amon, U.1    Hartmann, K.2    Horny, H.P.3
  • 43
    • 20144389124 scopus 로고    scopus 로고
    • Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes
    • Florian S., Krauth M.T., Simonitsch-Klupp I., et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005, 136(3):273-280.
    • (2005) Int Arch Allergy Immunol , vol.136 , Issue.3 , pp. 273-280
    • Florian, S.1    Krauth, M.T.2    Simonitsch-Klupp, I.3
  • 44
    • 37749039528 scopus 로고    scopus 로고
    • Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
    • Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63(2):226-232.
    • (2008) Allergy , vol.63 , Issue.2 , pp. 226-232
    • Brockow, K.1    Jofer, C.2    Behrendt, H.3
  • 45
    • 84859435404 scopus 로고    scopus 로고
    • Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion
    • Morgado J.M., Sanchez-Munoz L., Teodosio C.G., et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012, 25(4):516-521.
    • (2012) Mod Pathol , vol.25 , Issue.4 , pp. 516-521
    • Morgado, J.M.1    Sanchez-Munoz, L.2    Teodosio, C.G.3
  • 46
    • 37349073347 scopus 로고    scopus 로고
    • Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis
    • Hahn H.P., Hornick J.L. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007, 31(11):1669-1676.
    • (2007) Am J Surg Pathol , vol.31 , Issue.11 , pp. 1669-1676
    • Hahn, H.P.1    Hornick, J.L.2
  • 47
    • 0028881815 scopus 로고
    • The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
    • Schwartz L.B., Sakai K., Bradford T.R., et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. JClin Invest 1995, 96(6):2702-2710.
    • (1995) JClin Invest , vol.96 , Issue.6 , pp. 2702-2710
    • Schwartz, L.B.1    Sakai, K.2    Bradford, T.R.3
  • 48
    • 0033945410 scopus 로고    scopus 로고
    • Treatment of systemic mast cell disorders
    • vii
    • Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14(3):659-687. vii.
    • (2000) Hematol Oncol Clin North Am , vol.14 , Issue.3 , pp. 659-687
    • Worobec, A.S.1
  • 49
    • 0025302361 scopus 로고
    • Cromolyn sodium in the management of systemic mastocytosis
    • Horan R.F., Sheffer A.L., Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. JAllergy Clin Immunol 1990, 85(5):852-855.
    • (1990) JAllergy Clin Immunol , vol.85 , Issue.5 , pp. 852-855
    • Horan, R.F.1    Sheffer, A.L.2    Austen, K.F.3
  • 50
    • 0020683503 scopus 로고
    • Intervention with epinephrine in hypotension associated with mastocytosis
    • Turk J., Oates J.A., Roberts L.J. Intervention with epinephrine in hypotension associated with mastocytosis. JAllergy Clin Immunol 1983, 71(2):189-192.
    • (1983) JAllergy Clin Immunol , vol.71 , Issue.2 , pp. 189-192
    • Turk, J.1    Oates, J.A.2    Roberts, L.J.3
  • 51
    • 0030742614 scopus 로고    scopus 로고
    • Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis
    • Godt O., Proksch E., Streit V., et al. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997, 195(1):35-39.
    • (1997) Dermatology , vol.195 , Issue.1 , pp. 35-39
    • Godt, O.1    Proksch, E.2    Streit, V.3
  • 52
    • 0021990197 scopus 로고
    • Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes
    • Czarnetzki B.M., Rosenbach T., Kolde G., et al. Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 1985, 277(2):105-113.
    • (1985) Arch Dermatol Res , vol.277 , Issue.2 , pp. 105-113
    • Czarnetzki, B.M.1    Rosenbach, T.2    Kolde, G.3
  • 53
    • 0025978296 scopus 로고
    • Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids
    • Guzzo C., Lavker R., Roberts L.J., et al. Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids. Arch Dermatol 1991, 127(2):191-196.
    • (1991) Arch Dermatol , vol.127 , Issue.2 , pp. 191-196
    • Guzzo, C.1    Lavker, R.2    Roberts, L.J.3
  • 54
    • 0022343136 scopus 로고
    • Treatment of urticaria pigmentosa with corticosteroids
    • Barton J., Lavker R.M., Schechter N.M., et al. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 1985, 121(12):1516-1523.
    • (1985) Arch Dermatol , vol.121 , Issue.12 , pp. 1516-1523
    • Barton, J.1    Lavker, R.M.2    Schechter, N.M.3
  • 55
    • 0023078845 scopus 로고
    • Mastocytosis with malabsorption, myelofibrosis, and massive ascites
    • Reisberg I.R., Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 1987, 82(1):54-60.
    • (1987) Am J Gastroenterol , vol.82 , Issue.1 , pp. 54-60
    • Reisberg, I.R.1    Oyakawa, S.2
  • 56
    • 0027983756 scopus 로고
    • Aretrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis
    • Chen C.C., Andrich M.P., Mican J.M., et al. Aretrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. JNucl Med 1994, 35(9):1471-1475.
    • (1994) JNucl Med , vol.35 , Issue.9 , pp. 1471-1475
    • Chen, C.C.1    Andrich, M.P.2    Mican, J.M.3
  • 57
    • 79960798350 scopus 로고    scopus 로고
    • Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis
    • Laroche M., Livideanu C., Paul C., et al. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011, 124(8):776-778.
    • (2011) Am J Med , vol.124 , Issue.8 , pp. 776-778
    • Laroche, M.1    Livideanu, C.2    Paul, C.3
  • 58
    • 84879372052 scopus 로고    scopus 로고
    • Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management
    • Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013, 88(7):612-624.
    • (2013) Am J Hematol , vol.88 , Issue.7 , pp. 612-624
    • Pardanani, A.1
  • 59
    • 0026570013 scopus 로고
    • Response to interferon alfa-2b in a patient with systemic mastocytosis
    • Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. NEngl J Med 1992, 326(9):619-623.
    • (1992) NEngl J Med , vol.326 , Issue.9 , pp. 619-623
    • Kluin-Nelemans, H.C.1    Jansen, J.H.2    Breukelman, H.3
  • 60
    • 0031943841 scopus 로고    scopus 로고
    • Response of severe systemic mastocytosis to interferon alpha
    • Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998, 138(3):489-495.
    • (1998) Br J Dermatol , vol.138 , Issue.3 , pp. 489-495
    • Butterfield, J.H.1
  • 61
    • 0345167915 scopus 로고    scopus 로고
    • Cladribine therapy for systemic mastocytosis
    • Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102(13):4270-4276.
    • (2003) Blood , vol.102 , Issue.13 , pp. 4270-4276
    • Kluin-Nelemans, H.C.1    Oldhoff, J.M.2    Van Doormaal, J.J.3
  • 62
    • 73349111582 scopus 로고    scopus 로고
    • Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    • Lim K.H., Pardanani A., Butterfield J.H., et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84(12):790-794.
    • (2009) Am J Hematol , vol.84 , Issue.12 , pp. 790-794
    • Lim, K.H.1    Pardanani, A.2    Butterfield, J.H.3
  • 63
    • 68649118339 scopus 로고    scopus 로고
    • Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
    • Vega-Ruiz A., Cortes J.E., Sever M., et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009, 33(11):1481-1484.
    • (2009) Leuk Res , vol.33 , Issue.11 , pp. 1481-1484
    • Vega-Ruiz, A.1    Cortes, J.E.2    Sever, M.3
  • 64
    • 33645687784 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    • Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108(1):286-291.
    • (2006) Blood , vol.108 , Issue.1 , pp. 286-291
    • Shah, N.P.1    Lee, F.Y.2    Luo, R.3
  • 65
    • 10744228486 scopus 로고    scopus 로고
    • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    • Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102(9):3093-3096.
    • (2003) Blood , vol.102 , Issue.9 , pp. 3093-3096
    • Pardanani, A.1    Ketterling, R.P.2    Brockman, S.R.3
  • 66
    • 27144506215 scopus 로고    scopus 로고
    • Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
    • Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106(8):2865-2870.
    • (2005) Blood , vol.106 , Issue.8 , pp. 2865-2870
    • Gotlib, J.1    Berube, C.2    Growney, J.D.3
  • 67
    • 78649504351 scopus 로고    scopus 로고
    • Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study
    • Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85(12):921-925.
    • (2010) Am J Hematol , vol.85 , Issue.12 , pp. 921-925
    • Paul, C.1    Sans, B.2    Suarez, F.3
  • 68
    • 54349097778 scopus 로고    scopus 로고
    • Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    • Aichberger K.J., Sperr W.R., Gleixner K.V., et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008, 38(11):869-873.
    • (2008) Eur J Clin Invest , vol.38 , Issue.11 , pp. 869-873
    • Aichberger, K.J.1    Sperr, W.R.2    Gleixner, K.V.3
  • 69
    • 32844466631 scopus 로고    scopus 로고
    • Apilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    • Nakamura R., Chakrabarti S., Akin C., et al. Apilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006, 37(4):353-358.
    • (2006) Bone Marrow Transplant , vol.37 , Issue.4 , pp. 353-358
    • Nakamura, R.1    Chakrabarti, S.2    Akin, C.3
  • 70
    • 0025136860 scopus 로고
    • Splenectomy in the management of systemic mast cell disease
    • Friedman B., Darling G., Norton J., et al. Splenectomy in the management of systemic mast cell disease. Surgery 1990, 107(1):94-100.
    • (1990) Surgery , vol.107 , Issue.1 , pp. 94-100
    • Friedman, B.1    Darling, G.2    Norton, J.3
  • 72
    • 44849118922 scopus 로고    scopus 로고
    • Phenotypic and genotypic characteristics of mastocytosis according to the age of onset
    • Lanternier F., Cohen-Akenine A., Palmerini F., et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One 2008, 3(4):e1906.
    • (2008) PLoS One , vol.3 , Issue.4
    • Lanternier, F.1    Cohen-Akenine, A.2    Palmerini, F.3
  • 73
    • 18744387717 scopus 로고    scopus 로고
    • Pediatric cutaneous mastocytosis: a review of 180 patients
    • Ben-Amitai D., Metzker A., Cohen H.A. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J 2005, 7(5):320-322.
    • (2005) Isr Med Assoc J , vol.7 , Issue.5 , pp. 320-322
    • Ben-Amitai, D.1    Metzker, A.2    Cohen, H.A.3
  • 74
    • 84867294846 scopus 로고    scopus 로고
    • Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22)
    • Gadage V.S., Kadam Amare P.S., Galani K.S., et al. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22). Indian J Pathol Microbiol 2012, 55(3):409-412.
    • (2012) Indian J Pathol Microbiol , vol.55 , Issue.3 , pp. 409-412
    • Gadage, V.S.1    Kadam Amare, P.S.2    Galani, K.S.3
  • 75
    • 80455158048 scopus 로고    scopus 로고
    • Myelomastocytic leukemia with t(8;21) in a 3-year-old child
    • Intzes S., Wiersma S., Meyerson H.J. Myelomastocytic leukemia with t(8;21) in a 3-year-old child. JPediatr Hematol Oncol 2011, 33(8):e372-e375.
    • (2011) JPediatr Hematol Oncol , vol.33 , Issue.8
    • Intzes, S.1    Wiersma, S.2    Meyerson, H.J.3
  • 76
    • 34249985527 scopus 로고    scopus 로고
    • Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states
    • Lee J.W., Yang W.S., Chung S.Y., et al. Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states. JPediatr Hematol Oncol 2007, 29(6):412-415.
    • (2007) JPediatr Hematol Oncol , vol.29 , Issue.6 , pp. 412-415
    • Lee, J.W.1    Yang, W.S.2    Chung, S.Y.3
  • 77
    • 79961181551 scopus 로고    scopus 로고
    • Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia
    • Mahadeo K.M., Wolgast L., McMahon C., et al. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr Blood Cancer 2011, 57(4):684-687.
    • (2011) Pediatr Blood Cancer , vol.57 , Issue.4 , pp. 684-687
    • Mahadeo, K.M.1    Wolgast, L.2    McMahon, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.